

*Amendment*

U.S. Serial No. 08/921,060

Attorney Reference: 037003-0275463

Page 2

28. The method of claim 16 wherein said chimeric anti-CD20 antibody contains the variable light sequence contained in SEQ ID NO. 7.

29. The method of claim 23 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence contained in SEQ ID NO. 11.

30. The method of claim 23 wherein said chimeric anti-CD20 antibody contains the variable light sequence contained in SEQ ID NO. 7.

31. The method of claim 24 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence contained in SEQ ID NO: 11.

32. The method of claim 24 wherein said chimeric anti-CD20 antibody contains the variable light sequence contained in SEQ ID NO. 7.

33. The method of claim 24 which further includes the administration of at least one chemotherapeutic agent.

34. The method of claim 33 wherein said at least one chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, vincristine and prednisone.

35. The method of claim 11 which further includes the administration of a radiolabeled anti-CD20 antibody.

36. The method of claim 35 wherein said radiolabeled antibody is a murine anti-CD20 antibody.

37. The method of claim 16 which further includes the demonstration of a radiolabeled anti-CD20 antibody.

38. The method of claim 37 wherein said radiolabeled anti-CD20 antibody is a murine anti-CD20 antibody.

39. The method of claim 23 which further includes the administration of a radiolabeled anti-CD20 antibody.

40. The method of claim 39 wherein said radiolabeled anti-CD20 antibody is a murine anti-CD20 antibody.

41. The method of claim 24 which further includes the administration of a radiolabeled anti-CD20 antibody.